Pre-transplant multidrug-resistant infections in liver transplant recipients-epidemiology and impact on transplantation outcome.
ESBL-producing
Enterobacterales
carbapenem resistance
dialysis
meld
mortality
retransplantation
risk factors
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
25 Oct 2023
25 Oct 2023
Historique:
revised:
22
09
2023
received:
30
05
2023
accepted:
17
10
2023
medline:
25
10
2023
pubmed:
25
10
2023
entrez:
25
10
2023
Statut:
aheadofprint
Résumé
Cirrhotic patients are highly exposed to healthcare services and antibiotics. Although pre-liver transplantation (LT) infections are directly related to the worsening of liver function, the impact of these infections on LT outcomes is still unclear. This study aimed to identify the effect of multidrug-resistant microorganism (MDRO) infections before LT on survival after LT. Retrospective study that included patients who underwent LT between 2010 and 2019. Variables analyzed were related to patients' comorbidities, underlying diseases, time on the waiting list, antibiotic use, LT surgery, and occurrences post-LT. Multivariate analyses were performed using logistic regression, and Cox regression for survival analysis. A total of 865 patients were included; 351 infections were identified in 259 (30%) patients, of whom 75 (29%) had ≥1 pre-LT MDRO infection. The most common infection was spontaneous bacterial peritonitis (34%). The agent was identified in 249(71%), 53(15%) were polymicrobial. The most common microorganism was Klebsiella pneumoniae (18%); the most common MDRO was ESBL-producing Enterobacterales (16%), and carbapenem-resistant (CR) Enterobacterales (10%). Factors associated with MDRO infections before LT were previous use of therapeutic cephalosporin (p = .001) and fluoroquinolone (p = .001), SBP prophylaxis (p = .03), ACLF before LT (p = .03), and days of hospital stay pre-LT (p < .001); HCC diagnosis was protective (p = .01). Factors associated with 90-day mortality after LT were higher MELD on inclusion to the waiting list (p = .02), pre-LT MDRO infection (p = .04), dialysis after LT (p < .001), prolonged duration of LT surgery (p < .001), post-LT CR-Gram-negative bacteria infection (p < .001), and early retransplantation (p = .004). MDRO infections before LT have an important impact on survival after LT.
Sections du résumé
BACKGROUND
BACKGROUND
Cirrhotic patients are highly exposed to healthcare services and antibiotics. Although pre-liver transplantation (LT) infections are directly related to the worsening of liver function, the impact of these infections on LT outcomes is still unclear. This study aimed to identify the effect of multidrug-resistant microorganism (MDRO) infections before LT on survival after LT.
METHODS
METHODS
Retrospective study that included patients who underwent LT between 2010 and 2019. Variables analyzed were related to patients' comorbidities, underlying diseases, time on the waiting list, antibiotic use, LT surgery, and occurrences post-LT. Multivariate analyses were performed using logistic regression, and Cox regression for survival analysis.
RESULTS
RESULTS
A total of 865 patients were included; 351 infections were identified in 259 (30%) patients, of whom 75 (29%) had ≥1 pre-LT MDRO infection. The most common infection was spontaneous bacterial peritonitis (34%). The agent was identified in 249(71%), 53(15%) were polymicrobial. The most common microorganism was Klebsiella pneumoniae (18%); the most common MDRO was ESBL-producing Enterobacterales (16%), and carbapenem-resistant (CR) Enterobacterales (10%). Factors associated with MDRO infections before LT were previous use of therapeutic cephalosporin (p = .001) and fluoroquinolone (p = .001), SBP prophylaxis (p = .03), ACLF before LT (p = .03), and days of hospital stay pre-LT (p < .001); HCC diagnosis was protective (p = .01). Factors associated with 90-day mortality after LT were higher MELD on inclusion to the waiting list (p = .02), pre-LT MDRO infection (p = .04), dialysis after LT (p < .001), prolonged duration of LT surgery (p < .001), post-LT CR-Gram-negative bacteria infection (p < .001), and early retransplantation (p = .004).
CONCLUSION
CONCLUSIONS
MDRO infections before LT have an important impact on survival after LT.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15173Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Angeli P, Bernardi M, Villanueva C, et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. 10.1016/j.jhep.2018.03.024
Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol. 2021;75:S67-S81. 10.1016/j.jhep.2020.11.013
Piano S, Angeli P. Bacterial infections in cirrhosis as a cause or consequence of decompensation? Clin Liver Dis. 2021;25(2):357-372. 10.1016/j.cld.2021.01.006
Piano S, Singh V, Caraceni P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology. 2019;156(5):1368-1380.e10. 10.1053/j.gastro.2018.12.005
Onorato L, Monari C, Capuano S, Grimaldi P, Coppola N. Prevalence and therapeutic management of infections by Multi-Drug-Resistant Organisms (MDROs) in patients with liver cirrhosis: a narrative review. Antibiotics. 2022;11(2):232. 10.3390/antibiotics11020232
Freire MP, Oshiro ICVS, Pierrotti LC, et al. Carbapenem-resistant Enterobacteriaceae acquired before liver transplantation: impact on recipient outcomes. Transplantation. 2017;101(4):811-820. 10.1097/TP.0000000000001620
Baganate F, Beal EW, Tumin D, et al. Early mortality after liver transplantation: defining the course and the cause. Surgery. 2018;164(4):694-704. 10.1016/j.surg.2018.04.039
Leibovici-Weissman Y, Anchel N, Nesher E, Leshno M, Shlomai A. Early post-liver transplantation infections and their effect on long-term survival. Transpl Infect Dis. 2021;23(4):e13673. 10.1111/tid.13673
Moon HH, Kim T-S, Song S, et al. Early vs late liver retransplantation: different characteristics and prognostic factors. Transplant Proc. 2018;50(9):2668-2674. 10.1016/j.transproceed.2018.03.040
Giannella M, Freire M, Rinaldi M, et al. Development of a risk prediction model for carbapenem-resistant Enterobacteriaceae infection after liver transplantation: a multinational cohort study. Clin Infect Dis. 2021;73(4):e955-e966. 10.1093/cid/ciab109
Zhang W, Wang W, Kang M, et al. Bacterial and fungal infections after liver transplantation: microbial epidemiology, risk factors for infection and death with infection. Ann Transplant. 2020;25:25. 10.12659/AOT.921591
Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281. 10.1111/j.1469-0691.2011.03570.x
CDC/NHSN. CDC/NHSN Surveillance Definitions for Specific Types of Infections. Published 2021. Accessed April 24, 2021. https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf
Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-1048. 10.1002/hep.31884
Weinstein MP, Patel JB, Bobenchik AM, et al. M100 performance standards for antimicrobial susceptibility testing a CLSI supplement for global application. Performance Standards for Antimicrobial Susceptibility Testing Performance Standards for Antimicrobial Susceptibility Testing; 2020.
Baijal R, Amarapurkar D, Praveen Kumar HR, et al. A multicenter prospective study of infections related morbidity and mortality in cirrhosis of liver. Indian J Gastroenterol. 2014;33(4):336-342. 10.1007/s12664-014-0461-3
Gupta T, Lochan D, Verma N, et al. Prediction of 28-day mortality in acute decompensation of cirrhosis through the presence of multidrug-resistant infections at admission. J Gastroenterol Hepatol. 2020;35(3):461-466. 10.1111/jgh.14788
Salerno F, Borzio M, Pedicino C, et al. The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. Liver Int. 2017;37(1):71-79. 10.1111/liv.13195
Piano S, Tonon M, Angeli P. Changes in the epidemiology and management of bacterial infections in cirrhosis. Clin Mol Hepatol. 2021;27(3):437-445. 10.3350/cmh.2020.0329
Cinar G, Kalkan İA, Azap A, et al. Carbapenemase-producing bacterial infections in patients with liver transplant. Transplant Proc. 2019;51(7):2461-2465. 10.1016/j.transproceed.2019.02.050
Heldman MR, Ngo S, Dorschner PB, Helfrich M, Ison MG. Pre- and post-transplant bacterial infections in liver transplant recipients. Transpl Infect Dis. 2019;21(5):e13152. 10.1111/tid.13152
Sun H-Y, Cacciarelli TV, Singh N. Impact of pretransplant infections on clinical outcomes of liver transplant recipients. Liver Transplant. 2010;16(2):222-228. 10.1002/lt.21982
Lin K-H, Liu J-W, Chen C-L, et al. Impacts of pretransplant infections on clinical outcomes of patients with acute-on-chronic liver failure who received living-donor liver transplantation. PLoS ONE. 2013;8(9):e72893. 10.1371/journal.pone.0072893
Taimur S, Pouch SM, Zubizarreta N, et al. Impact of pre-transplant carbapenem-resistant Enterobacterales colonization and/or infection on solid organ transplant outcomes. Clin Transplant. 2021;35(4):e14239. 10.1111/ctr.14239
Ferstl PG, Filmann N, Brandt C, et al. The impact of carbapenem resistance on clinical deterioration and mortality in patients with liver disease. Liver Int. 2017;37(10):1488-1496. 10.1111/liv.13438
Freire MP, Carvalho LB, Reusing JO, et al. Carbapenem-resistant Enterobacteriaceae among kidney transplant recipients-insights on the risk of acquisition and CRE infection. Infect Dis (Auckl). 2021;53(6):430-439. 10.1080/23744235.2021.1887511
Russell DL, Flood A, Zaroda TE, et al. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant. 2008;8(8):1737-1743. 10.1111/j.1600-6143.2008.02304.x
Chiang D, Dingle TC, Belga S, et al. Association between gut colonization of vancomycin-resistant enterococci and liver transplant outcomes. Transpl Infect Dis. 2022;24(3):e13821. 10.1111/tid.13821
Bert F, Larroque B, Paugam-Burtz C, et al. Pretransplant fecal carriage of extended-spectrum β-lactamase-producing enterobacteriaceae and infection after liver transplant, France. Emerg Infect Dis. 2012;18(6):908-916. 10.3201/eid1806.110139
Magro B, Mazzola A, Munteanu M, et al. Consequences of extended spectrum beta-lactamase-producing Enterobacteriaceae and methicillin-resistant staphylococcus aureus carriage in awaiting liver transplant patients. Liver Transplant. 2021;27(1):43-54. 10.1002/lt.25897
Fernández J, Prado V, Trebicka J, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J Hepatol. 2019;70(3):398-411. 10.1016/j.jhep.2018.10.027
Salvalaggio P, Afonso RC, Pereira LA, Ferraz-Neto B-H. O sistema MELD e a mortalidade em lista de espera para transplante de fígado em países em desenvolvimento: lições aprendidas em São Paulo. Einstein (São Paulo). 2012;10(3):278-285. 10.1590/S1679-45082012000300004
Bartoletti M, Giannella M, Lewis R, et al. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. Clin Microbiol Infect. 2018;24(5):546.e1-546.e8. 10.1016/j.cmi.2017.08.001
Freire MP, Rinaldi M, Terrabuio DRB, et al. Prediction models for carbapenem-resistant Enterobacterales carriage at liver transplantation: a multicenter retrospective study. Transpl Infect Dis. 2022;24(6):e13920. 10.1111/tid.13920